Key Highlights

  • Net loss was $15.636 million, or $0.12 per share, versus $13.574 million, or $0.11, a year earlier.
  • Cash, cash equivalents and investments totaled $114.3 million, down from about $156.1 million at year-end 2025.
  • Total operating expenses rose about 10% to $16.947 million.
  • Revenue was $234,000, from grants and an early access program, with none a year earlier.
  • Voyager instrument availability is planned for the middle of 2027, with twenty proteoform assays planned through mid-2028.

Nautilus Biotechnology Earnings: How Long Does $114.3M of Cash Fund the Voyager Plan?

Nautilus Biotechnology (NASDAQ:NAUT) reported third-quarter results on Tuesday, October 27, with a net loss of $15.636 million, or $0.12 per share, compared with $13.574 million, or $0.11, a year earlier. The screen showed an EPS estimate of a $0.14 loss, so the result was narrower than expected as screened.

Cash, cash equivalents and investments stood at $114.3 million at September 30, down about $41.8 million from roughly $156.1 million at year-end 2025. The release did not state a runway figure.

Nine-month cash used in operations was $40.1 million, compared with $38.3 million a year earlier. By a simple calculation, that pace annualises to roughly $53 million, which would cover about two years of operating burn.

Operating Costs: Why Did the Loss Widen 15%?

Nautilus develops a platform for measuring proteins and proteoforms, the many variants of each protein. Total operating expenses rose about 10% to $16.947 million from $15.472 million. Research and development was $10.176 million, up about 6%, and selling, general and administrative expense was $6.771 million, up about 15%.

Management cited higher laboratory and professional services costs and higher salaries and benefits. Interest income fell to $1.173 million from $1.903 million. The net loss widened about 15%.

For the nine months, the picture is steadier. The net loss was $44.802 million, or $0.35 per share, versus $45.220 million, or $0.36. Research and development fell about 6% to $29.496 million.

Revenue Starts: What Do Grants and Early Access Add?

Total revenue was $234,000, split between $208,000 of grant revenue and $26,000 of service revenue. The grant revenue is linked mainly to a grant from The Michael J. Fox Foundation, and the service revenue to the Iterative Mapping Early Access Program. There was no revenue in the third quarter of 2025, and nine-month revenue was $424,000.

After quarter end, Nautilus announced participation in SEEDS, a four-year, multi-center consortium funded by ARPA-H. The company expects up to $6 million to deploy Voyager to measure proteoforms in Alzheimer's disease and cancer. The release cautions that the funding may be reduced, delayed or terminated.

Roadmap Rationale: Is Proteoform Assay Development on Schedule?

The chief executive called the quarter an important step in demonstrating the scalability of Iterative Mapping on Voyager. A paper published after peer evaluation in Nature Methods described how the method reveals proteoforms tied to biology and disease.

At World HUPO 2026, the company shared first development data on oncology proteoform assays, including AKT1. Management said performance matched the Tau assay, supporting the view that results are repeatable across targets. The company plans twenty assays through mid-2028.

The release gave no full-year financial guidance. Voyager is not yet commercially available and remains subject to technical development and validation, and timelines could slip.

What to Watch Next: Can Burn Stay Near $53M a Year Ahead of Mid-2027?

Total assets were $148.9 million, liabilities $32.4 million and equity $116.6 million. Investors will watch operating expense growth, further assay releases, the SEEDS programme and any update to the mid-2027 instrument date.